# Venmax Drugs (NSE: VENMAX) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/VENMAX · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹17 Cr, it ranks 3677th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was −0.2% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹4 Cr (+1,093.9% year on year) and net profit ₹0 Cr (−85.9%), on a standalone basis. Promoters held 10.46% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹17 Cr |
| ROE | −0.2% (FY25) |
| ROCE | −0.3% (FY25) |
| Debt to equity | 0.01 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹4 Cr | +1,093.9% | ₹0 Cr | −85.9% | ₹0.20 |
| Q3 FY26 | ₹2 Cr | +675.0% | ₹0 Cr | — | ₹0.05 |
| Q2 FY26 | ₹1 Cr | +676.5% | ₹0 Cr | — | ₹0.05 |
| Q1 FY26 | ₹1 Cr | +1,110.0% | ₹0 Cr | +300.0% | ₹0.07 |
| Q4 FY25 | ₹0 Cr | — | ₹1 Cr | +1,460.0% | ₹1.48 |
| Q3 FY25 | ₹0 Cr | — | −₹1 Cr | −1,766.7% | −₹0.95 |
| Q2 FY25 | ₹0 Cr | — | −₹0 Cr | — | −₹0.58 |
| Q1 FY25 | ₹0 Cr | — | ₹0 Cr | −50.0% | ₹0.02 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1 Cr | −₹0 Cr |
| FY24 | ₹0 Cr | ₹0 Cr |
| FY23 | ₹0 Cr | ₹0 Cr |
| FY22 | ₹0 Cr | ₹2 Cr |
| FY21 | ₹0 Cr | −₹0 Cr |
| FY20 | ₹0 Cr | −₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 10.46%
- Non-institutions: 89.54%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Desh Rakshak](https://app.pivotnow.in/stock/DESHRAK) | — | ₹19 Cr | — | — |
| [Nidan Lab](https://app.pivotnow.in/stock/NIDAN) | ₹12.65 | ₹18 Cr | — | — |
| [Vanta Bioscienc](https://app.pivotnow.in/stock/VANTABIO) | — | ₹17 Cr | — | — |
| [Zenith Health](https://app.pivotnow.in/stock/ZENITHHE) | — | ₹17 Cr | — | — |
| [Family Care Hos](https://app.pivotnow.in/stock/FAMILYCARE) | — | ₹16 Cr | — | — |
| [Colinz Labs](https://app.pivotnow.in/stock/COLINZ) | — | ₹15 Cr | — | — |

## Questions and answers

### What is the market cap of Venmax Drugs?

Venmax Drugs' market capitalisation is ₹17 Cr (₹17 Cr) at the 22 Oct 2026 close, ranking 3677th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Venmax Drugs?

Return on equity was −0.2% in FY25 and return on capital employed was −0.3% in FY25 (standalone figures).

### Is Venmax Drugs a debt-free company?

Venmax Drugs is close to debt-free: its debt-to-equity ratio was 0.01 in FY25.

### What were Venmax Drugs' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Venmax Drugs reported revenue of ₹4 Cr, +1,093.9% year on year, and net profit of ₹0 Cr, −85.9% year on year.

### What is the shareholding pattern of Venmax Drugs?

As of 30 Jun 2026: promoters 10.46%, non-institutions 89.54%.

### Who are Venmax Drugs' competitors?

The listed Pharma & Healthcare companies closest to Venmax Drugs by market cap are Desh Rakshak, Nidan Lab, Vanta Bioscienc, Zenith Health, Family Care Hos and Colinz Labs.

### Is Venmax Drugs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Venmax Drugs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VENMAX against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.